These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 27807503)

  • 1. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Clara JA; Sallman DA; Padron E
    Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic/myeloproliferative neoplasms.
    Hyjek E; Vardiman JW
    Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
    Kuendgen A; Kasprzak A; Germing U
    Front Oncol; 2021; 11():778741. PubMed ID: 34869027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
    Talati C; Padron E
    Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetics of MDS/MPN overlap syndromes.
    Hunter AM; Padron E
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
    Patnaik MM; Lasho T
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
    Zoi K; Cross NC
    Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.
    Fontana D; Elli EM; Pagni F; Piazza R
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.
    Gerds AT
    Curr Hematol Malig Rep; 2014 Dec; 9(4):400-6. PubMed ID: 25195196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
    Smith BN; Savona M; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):1-8. PubMed ID: 30555034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
    Fei F; Jariwala A; Pullarkat S; Loo E; Liu Y; Tizro P; Ali H; Otoukesh S; Amanam I; Artz A; Ally F; Telatar M; Nakamura R; Marcucci G; Afkhami M
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peculiarities in the Diagnosis Approach of MDS /MPN-U Patients.
    Triantafyllidis I; Ciobanu A; Stanca O; Draghici C; Angelescu S; Tapelea E
    Maedica (Bucur); 2012 Jun; 7(2):173-6. PubMed ID: 23401728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
    Shallis RM; Zeidan AM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.
    Hochman MJ; Savani BN; Jain T
    EJHaem; 2021 Aug; 2(3):607-615. PubMed ID: 35844680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
    Wan Z; Han B
    Front Oncol; 2020; 10():579221. PubMed ID: 33117717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.